Poor sensitivity of plasma p‐tau181 to intermediate ADNC may help explain the divergences between previous findings: one study showed no difference in plasma p‐tau181 in LBSD who were PET‐Aβ positive versus PET‐Aβ negative,20 although others have found that plasma p‐tau181 does associate with PET‐tau status in LBSD21 and that it associates with cognitive decline in DLB.22 The gene discussed is MAPT; the disease is Lewy body dementia.